Today (8 April) it was revealed that over 700,000 AstraZeneca doses manufactured in the UK are being sent to Australia - with a confirmed 300,000 vaccines in Sydney at the end of February.
New data from the REACT study finds that the prevalence of COVID is down by 60% in one month, but primary school children have the highest COVID infection levels.
The UK's medical authorities cleared continued use of AstraZeneca, but say that 18-29 year olds should take an alternative vaccine to AstraZeneca if possible.
ONS data from January shows that only 49% of Black British adults would take the COVID vaccine - the UK Government acknowledges that others are wary about the intention of "some institutions and authorities".
According to new ONS data, 36% of UK people who are vaccine hesitant have strong side effect fears - while a further 12% fear needles, and 22% think vaccines could impact fertility.
The new digital hardware framework could save the NHS and wider public sector up to £250 million - building on the success of many services transitioning to remote working.
Logan Finucan, Access Partnership, explains how the European Commission has launched the process towards the adoption of two adequacy decisions for personal dataflows to the UK.
The Dexamethasone steroid has been used across the globe to help treat COVID-19 in the ICU - leading to atleast one million survivors of hospitalisation from the virus.
More than 120 governments have announced their commitments to achieve net zero targets by the middle of this century, so will this become a central focus in 2021?
The safety committee of the European Medicines Agency said the investigation did not prove that AstraZeneca vaccinations cause blood clots - describing the possibility as an "extremely small likelihood".
Faisal Abbasi, Managing Director Western Europe and MEMA, Amelia, explores how the government can make the most of its Help to Grow scheme to boost entrepreneurship and create the next generation of technology leaders.
The NHS released new information explaining that there would be a vaccine shortage in the UK from 29 March, meaning under-50s will wait longer for their first jab as second doses are given to the most vulnerable cohorts.
